lung cancer
Conditions
Interventions
Group 1:Gefinitib/Erlotinib
Group 2:Gefinitib/Erlotinib & Basil
Group 3:standard chemotherapy
Group 4:standard chemotherapy & basil
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed with non-same cell lung cancer by pathology; 2. TCM syndrome differentiation is qi deficiency and phlegm dampness syndrome; 3. Aged between 18-80 years old; 4. ECOG Performance Status 0-3; 5. Local lesions and/or distant metastatic lesions can be measured or evaluated; 6. Normal function of bone marrow, liver, kidney, heart and lung; 7. Estimated survival time more than 3 months; 8. Can understand the study well and sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. pregnant woman; 2. Patients with uncontrolled brain metastases; 3. Combine with other tumors; 4. Patients with mental disorders; 5. Combine with active tuberculosis and other serious infectious diseases; 6. Elimination criteria: (1) During the course of the experiment, if the patient requests to withdraw from the study, the reason for the withdrawal should be recorded as much as possible, and other treatment plans that are willing to accept should be taken; (2) If there is drug allergy or unanticipated serious adverse reactions during the treatment, and it may be related to the experimental drug, the treatment should be stopped in time and other treatment should be carried out.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| abundance of EGFR mutation; | — |
Secondary
| Measure | Time frame |
|---|---|
| BRCA1 and ERCC1 mRNA level;blood biochemical indexes;Response Rate; | — |
Countries
China
Contacts
Public ContactFeng Bing
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed